Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05774951 |
| Title | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) |
| Acronym | CAMBRIA-1 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS |